Received Oct 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | F4A7R | — |
first dose was administered on 23rd September 2025, and 2nd dose was administered on 29 September 2025; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 3-year-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) (batch number F4A7R, expiry date 06-JUN-2026) for prophylaxis. Concomitant products included Influenza vaccine inact split 3v (Flulaval). On 29-SEP-2025, the patient received the 2nd dose of FluLaval 2025-2026 season. On 29-SEP-2025, an unknown time after receiving FluLaval 2025-2026 season, the patient experienced drug dose administration interval too short (Verbatim: first dose was administered on 23rd September 2025, and 2nd dose was administered on 29 September 2025). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 30-SEP-2025 Reporter reported someone else gave a child an early 2nd dose of FluLaval. The child had never been vaccinated and was due for 2 doses. The first dose was administered on 23rd September 2025, and 2nd dose was administered on 29th September 2025.; Sender's Comments: US-GSK-US2025125441:Same reporter/Diffrent patient